Product
Belrestotug
Aliases
EOS884448, GSK4428859A
4 clinical trials
4 indications
Indication
CancerIndication
Head and NeckIndication
lung cancerIndication
Non-Small CellClinical trial
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2025-09-17
Clinical trial
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-01-17
Clinical trial
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-09-03
Clinical trial
A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)Status: Recruiting, Estimated PCD: 2028-09-19